Showing 119 of 119on this page. Filters & sort apply to loaded results; URL updates for sharing.119 of 119 on this page
Replimune stock rally 46% on leaked RP1 and RP2 clinical trial data
Replimune 2022 Investor Day: RP1 in Skin Cancer on Vimeo
Replimune Receives Complete Response Letter from FDA for RP1 Bio
Replimune receives CRL on BLA for RP1 for advanced melanoma | pharmaphorum
Replimune Faces Lawsuit After FDA Rejects RP1 Cancer Drug Application ...
Replimune FDA Meeting Update: RP1 Melanoma Drug Path Unclear | REPL ...
FDA Issues Complete Response Letter to Replimune for RP1 Combination ...
Replimune 获得 RP1 突破性疗法认定并向 FDA 提交 BLA - AIM 黑色素瘤基金会
Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the ...
Replimune 宣布 RP1 治疗晚期黑色素瘤的 BLA 获得接受和优先审查 - AIM at Melanoma Foundation
Replimune Group, Inc. (REPL) Stock: Soars 120% After FDA Accepts RP1 ...
Replimune Prepares for Type A Meeting With FDA on RP1
Replimune Prepares for Type A Meeting With FDA on RP1 | Dermatology Times
Replimune kickstarts Phase III melanoma trial studying RP1 ...
Replimune Group Plunges 77.36% After FDA Rejects RP1
Replimune Spotlights Late-Breaking RP1 Data at SITC 2025
Replimune Prepares for Type A Meeting With FDA on RP1 | Dermatology ...
Replimune ($REPL) FDA Rejection, Misleading Trial Claims, and RP1 ...
Replimune Presents New Analyses from the IGNYTE Study of RP1 plus ...
Eric Whitman: FDA’s Rejection of RP1 by Replimune - OncoDaily
Replimune Q3 loss $70.9M, RP1 PDUFA set for April 10 | REPL Stock News
Melanoma: FDA respinge la richiesta di Replimune per RP1
Replimune and Incyte to Collaborate on Clinical Trial to Study RP1 in ...
Kevin Harrington: FDA Accepts Replimune's Resubmission for RP1 in ...
Replimune Accepts FDA BLA Resubmission for RP1; PDUFA Apr 10, 2026 ...
FDA Accepts Replimune's BLA for RP1 + Nivolumab in Melanoma | OncoDaily ...
Replimune Announces First Patients Dosed in a Phase 1/2 Clinical Trial ...
Replimune's RP1 Shows 44% Response in Acral Melanoma | REPL Stock News
FDA Rejects Replimune’s RP1 Skin Cancer Therapy - Medicine to Market
Replimune’s RP1 + Nivolumab Shows Promising Results in Melanoma Study
Roth ups Replimune PT to $30 from $20 - BioTuesdays
Replimune's RP1 in Advanced Melanoma: Strategic Pathways and Risk ...
Replimune's RP1 Gains Breakthrough Status and Files FDA Application for ...
Replimune (REPL): Scientific Deep Dive for RP1, RP2, and Pipeline Products
Replimune’s RP1 + Nivolumab Shows Promising Results in Melanoma Study ...
Replimune Highlights RP1, RP2 Progress Ahead of JPM Conference ...
Replimune's RP1 Melanoma Therapy Nears FDA Decision with July PDUFA ...
Particle: FDA Accepts Replimune’s Resubmitted RP1 Melanoma Filing, Sets ...
RP1 Combined With Nivolumab in Advanced Anti–PD-1–Failed Melanoma ...
FDA Rejects Replimune Melanoma Drug RP1, Company Seeks Urgent Meeting ...
FDA Rejects Replimune’s RP1 Skin Cancer Therapy – Medicine to Market
FDA Issues Complete Response Letter for Replimune's RP1 Oncolytic ...
FDA Issues CRL for RP1 in Advanced Melanoma | Targeted Oncology ...
Replimune's RP1 Achieves 33% Response Rate in Anti-PD1 Failed Melanoma ...
Replimune's RP1 for Advanced Melanoma Has Received BLA Acceptance and ...
Replimune Phase 1 2 Protocol RPL-001-16 Amend 04 US Final V5.1 06Jul18 ...
Oncolytic Immunotherapy Pipeline | Replimune
Today, we presented new analyses from the IGNYTE study of RP1 plus ...
Replimune enrols first patient in Phase II CSCC study
Replimune Shares Surge on Regulatory Breakthrough
Diagram of RP1 gene and protein. Location of all published mutations in ...
After receiving a CRL for its RP1 oncolytic immunotherapy yesterday ...
Replimune, Inc.: Replimune Receives Complete Response Letter from FDA ...
Replimune Announces Positive Topline Primary Analysis Data by ...
Replimune Shows 33.6% ORR for RP1+nivolumab in melanoma | REPL Stock News
Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of ...
#breakingnews | Replimune | 46 comments
Broth Agency | Replimune Case Study
Replimune: The Rise Of Oncolytic Virus Therapies In Cancer Treatment ...
FDA拒绝批准一款溶瘤病毒医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Replimune's RP1: A New Hope for Advanced Melanoma patients
Last week, we shared a comprehensive update on RP1. The full ...
Replimune: A Misunderstood Contender In Oncolytics (NASDAQ:REPL ...
跌宕起伏！RP1重启上市，Replimune股价飙升医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
GRAPHIC
#replimune #rp1 #advancedmelanoma #oncolyticimmunotherapy #fdaapproval ...
Dissecting Replimune’s RP1’s Surprising Setback
Replimune, Incyte to study cancer combo therapy in CSCC patients
Replimune大跌77%：溶瘤病毒RP1被FDA拒绝批准 Armstrong 2025年7月22日，Replimune宣布溶瘤病毒疗法 ...
美国溶瘤病毒公司Replimune豪募12.5亿美元，开启PD1王炸联合癌症治疗新时代！ - 知乎
Navigating the Storm: Replimune's FDA Hurdles and the Resilience of ...
.png)
